Sophiris Bio (Sophiris Bio) Forward Dividend Yield % : 0.00% (As of May. 05, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Forward Dividend Yield %?

As of today (2024-05-05), the Forward Annual Dividend Yield of Sophiris Bio is 0.00%.

As of today (2024-05-05), the Trailing Annual Dividend Yield of Sophiris Bio is 0.00%.

SPHS's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.505
* Ranked among companies with meaningful Forward Dividend Yield % only.

Sophiris Bio's Dividends per Share for the three months ended in Sep. 2019 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Sophiris Bio's Forward Dividend Yield %

For the Biotechnology subindustry, Sophiris Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sophiris Bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Forward Dividend Yield % falls into.

Sophiris Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Sophiris Bio (OTCPK:SPHS) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Sophiris Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sophiris Bio (Sophiris Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1258 Prospect Street, La Jolla, CA, USA, 92037

Website

http://www.sophirisbio.com

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

Executives

Randall E Woods	director, officer: President & Chief Exec Officer	C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell	director
Gerald T Proehl	director
John Geltosky	director	685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn	director	PO BOX 676367, RANCHO SANTA FE CA 92067